Definium Therapeutics gets Breakthrough Therapy designation for DT120
Definium Therapeutics received Breakthrough Therapy designation for DT120 (lysergide) ODT in major depressive disorder after positive Phase 3 results.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.